EUVIMEDEUVIMED entdecken
Crossref

Prognostic significance of early tumor shrinkage in metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based combination therapy

Naoki Matsuyama, Takuto Hara, Hideto Ueki, Naoto Wakita, Yasuyoshi Okamura, Yukari Bando, Kotaro Suzuki, Tomoaki Terakawa, Koji Chiba, Akihisa Yao, Jun Teishima, Hideaki Miyake

International Journal of Clinical Oncology · 2026-07 · 31 (7) · 1316-1325

DOI: 10.1007/s10147-026-03046-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 19.05.2026. Verfasst von Naoki Matsuyama und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Kobe, Hyogo, 650-0017, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Immune Checkpoint Inhibitors. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitor (ICI)-based combination therapies have become the standard first-line treatment for metastatic renal cell carcinoma (mRCC). This study evaluated the prognostic significance of early tumor shrinkage in patients with mRCC treated with first-line ICI-based combination therapies. We retrospectively reviewed 169 mRCC patients who received nivolumab plus ipilimumab, pembrolizumab (or avelumab) plus axitinib, pembrolizumab plus lenvatinib, or nivolumab plus cabozantinib at Kobe University Hospital and its affiliated institutions. Patients were stratified into four groups according to early tumor shrinkage at the first imaging assessment after therapy initiation. The association between early tumor shrinkage and the overall survival (OS) was analyzed. The median early tumor shrinkage rate was 17.8%. Twenty-one patients (12.4%) had 50–100% shrinkage, 31 (18.3%) had 30–

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsHumansFemaleMalePrognosisRetrospective StudiesAgedMiddle AgedAged, 80 and overPhenylurea CompoundsAdultNivolumabPyridinesIpilimumabAxitinibAntibodies, Monoclonal, HumanizedQuinolinesAnilides

Stichwörter der Autor:innen

Early tumor shrinkageImmune checkpoint inhibitorOverall survivalPrognosisRenal cell carcinomaTumor burden

Substanzen

Immune Checkpoint InhibitorsPhenylurea CompoundsNivolumabpembrolizumabPyridinesIpilimumabAxitinibAntibodies, Monoclonal, HumanizedlenvatinibQuinolines

Autor:innen und Institutionen

  • Division of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Kobe, Hyogo, 650-0017, Japan.
  • Division of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Kobe, Hyogo, 650-0017, Japan. supermarimo85@gmail.com.

Zitieren

APA

Matsuyama, N., Hara, T., Ueki, H., Wakita, N., Okamura, Y., Bando, Y., Suzuki, K., Terakawa, T., Chiba, K., Yao, A., Teishima, J., & Miyake, H. (2026). Prognostic significance of early tumor shrinkage in metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based combination therapy. International Journal of Clinical Oncology, 31(7), 1316-1325. https://doi.org/10.1007/s10147-026-03046-7

Vancouver

Matsuyama N, Hara T, Ueki H, Wakita N, Okamura Y, Bando Y, et al. Prognostic significance of early tumor shrinkage in metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based combination therapy. International Journal of Clinical Oncology. 2026;31(7):1316-1325. doi:10.1007/s10147-026-03046-7

BibTeX
@article{Matsuyama2026,
  author = {Matsuyama, Naoki and Hara, Takuto and Ueki, Hideto and Wakita, Naoto and Okamura, Yasuyoshi and Bando, Yukari and Suzuki, Kotaro and Terakawa, Tomoaki and Chiba, Koji and Yao, Akihisa and Teishima, Jun and Miyake, Hideaki},
  title = {Prognostic significance of early tumor shrinkage in metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based combination therapy},
  journal = {International Journal of Clinical Oncology},
  year = {2026},
  volume = {31},
  number = {7},
  pages = {1316--1325},
  doi = {10.1007/s10147-026-03046-7}
}
Kostenlos starten →